Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle H Nelson

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
JCI Insight|March 15, 2017
Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansionJacob S Bowers, Michelle H Nelson, Kinga Majchrzak, et al.
Cancer Immunology, Immunotherapy : CII|January 31, 2016
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicKinga Majchrzak, Michelle H Nelson, Stefanie R Bailey, et al.
Journal of Immunology Research and Therapy|August 22, 2017
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer ImmunotherapiesLillian R Neal, Stefanie R Bailey, Megan M Wyatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2015
Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 SignalingJacob S Bowers, Michelle H Nelson, Sreenath Kundimi, et al.
Vaccine|January 10, 2012
Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signalingEvandro R Winkelmann, Douglas G Widman, Jingya Xia, et al.
Journal for Immunotherapy of Cancer|February 18, 2016
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioningMichelle H Nelson, Jacob S Bowers, Stefanie R Bailey, et al.
Frontiers in Immunology|October 17, 2017
PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8<sup>+</sup> T CellsJacob S Bowers, Kinga Majchrzak, Michelle H Nelson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 11, 2015
The inducible costimulator augments Tc17 cell responses to self and tumor tissueMichelle H Nelson, Sreenath Kundimi, Jacob S Bowers, et al.
Nature Communications|December 8, 2017
Human CD26<sup>high</sup> T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistenceStefanie R Bailey, Michelle H Nelson, Kinga Majchrzak, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Constructing the cure: engineering the next wave of antibody and cellular immune therapiesStefanie R Bailey, Eric Bartee, Kyle G Daniels, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
JCI Insight|March 15, 2017
Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansionJacob S Bowers, Michelle H Nelson, Kinga Majchrzak, et al.
Cancer Immunology, Immunotherapy : CII|January 31, 2016
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicKinga Majchrzak, Michelle H Nelson, Stefanie R Bailey, et al.
Journal of Immunology Research and Therapy|August 22, 2017
The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer ImmunotherapiesLillian R Neal, Stefanie R Bailey, Megan M Wyatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2015
Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 SignalingJacob S Bowers, Michelle H Nelson, Sreenath Kundimi, et al.
Vaccine|January 10, 2012
Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signalingEvandro R Winkelmann, Douglas G Widman, Jingya Xia, et al.
Journal for Immunotherapy of Cancer|February 18, 2016
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioningMichelle H Nelson, Jacob S Bowers, Stefanie R Bailey, et al.
Frontiers in Immunology|October 17, 2017
PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8<sup>+</sup> T CellsJacob S Bowers, Kinga Majchrzak, Michelle H Nelson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 11, 2015
The inducible costimulator augments Tc17 cell responses to self and tumor tissueMichelle H Nelson, Sreenath Kundimi, Jacob S Bowers, et al.
Nature Communications|December 8, 2017
Human CD26<sup>high</sup> T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistenceStefanie R Bailey, Michelle H Nelson, Kinga Majchrzak, et al.
Journal for Immunotherapy of Cancer|August 25, 2025
Constructing the cure: engineering the next wave of antibody and cellular immune therapiesStefanie R Bailey, Eric Bartee, Kyle G Daniels, et al.
Pageof 3